Rhodiola Rosea

Rhodiola is one of the best-selling adaptogens in the United States, and its evidence base does not support most of what it is sold for. Its strongest claims — a small acute boost to endurance, and modest relief of physical and mental fatigue under stress — earn a C. Cortisol, anxiety, mood, altitude sickness and weight loss all land at D: insufficient human evidence. That is not us being stingy. The National Center for Complementary and Integrative Health's current position is that "there isn't enough reliable evidence to determine whether rhodiola or its components are useful for any health-related purpose,"¹ and the Merck Manual's professional edition puts it just as bluntly: "There are no high-quality studies in people demonstrating that rhodiola is effective for treating any health condition."³ There is one more problem underneath all of it, which almost nobody writes about: a bottle labeled rhodiola may not contain much Rhodiola rosea. Here is the honest version, grade by grade.

What rhodiola actually is, and what "adaptogen" doesn't mean

Rhodiola rosea is an Arctic and alpine succulent — golden root, arctic root, roseroot — whose rhizome and root are used. Its two marker compound groups are the rosavins (rosavin, rosarin and rosin) and salidroside. The spec on nearly every label, 3% rosavins / 1% salidroside, is the commercial standard sold to manufacturers²² and the exact spec used in the trials — the 2004 endurance study dosed "200 mg Rhodiola rosea extract containing 3% rosavin + 1% salidroside."⁷ It is the one number on the label worth reading.

The detail that does most of the work later on this page: in the survey that established the marker, among 11 Rhodiola species tested, only R. rosea carried the rosavins.²² That is a strong rule rather than an absolute one — later researchers did find rosavins in R. sachalinensis, at lower concentrations than in R. rosea.²² But it holds for the substitution that actually matters: R. crenulata, used in Tibetan and Chinese medicine, contains salidroside and no rosavin.²² Rosavins are therefore both the actives and the closest thing the genus has to a species fingerprint.

"Adaptogen" is worth being skeptical about. It is a mid-20th-century Soviet coinage for a substance that supposedly raises non-specific resistance to stress — a traditional and marketing category, not a regulated pharmacological one. Rhodiola is one of the two herbs the word was invented around; ashwagandha is the other, and covers the history at more length. Europe illustrates the gap: the European Medicines Agency grants rhodiola root a traditional-use registration for "temporary relief of symptoms of stress, such as fatigue and sensation of weakness."²⁴ A traditional-use registration says a plant has been used that way for at least 30 years and looks plausible and safe — not that it has been shown to work — and this one caps the use at adults and two weeks without seeing a doctor.²⁴ Far smaller than the claim on the shelf.

The evidence, benefit by benefit

The grid above is the short version; below is the reasoning, strongest to weakest. Two discounts run through almost every row: the trials are small, and the most-cited positive ones were run on branded extracts by people connected to the companies that make them.

Physical and endurance performance

CLimited evidence

Rhodiola's best case, and still a C. A 2025 meta-analysis pooled 26 randomized controlled trials in 668 healthy participants and found significant improvements in VO2max (effect size 0.32), time to exhaustion (0.38) and time-trial performance (−0.40), plus lower creatine kinase and blood lactate and no effect on inflammatory markers.⁵ Read the fine print, though: those pooled estimates didn't each come from 26 trials. VO2max came from 11 studies, time to exhaustion from 7, time-trial performance from 5.⁵ The authors close by warning that "heterogeneity across studies warrants cautious interpretation."⁵

A 2023 systematic review of 13 trials in 263 participants named the reason for the discount outright: "unclear or high risk of bias in most of the studies included."⁶ Its most useful finding is about when rhodiola works. Acute supplementation improved endurance performance and perceived exertion; chronic supplementation improved anaerobic performance but not endurance.⁶ A 2004 crossover study makes the same point in miniature: 200 mg taken one hour before exercise raised time to exhaustion from 16.8 to 17.2 minutes, while four weeks of 200 mg daily "did not alter any of the variables measured."⁷ For endurance, the evidence points at a single dose before the session, not a daily habit.

Mental fatigue under stress or shift work

CLimited evidence

The most contradictory grade on the page, and it sits at C mostly because of who ran the positive studies. A systematic review of 11 trials found 3 of 5 mental-fatigue trials positive (and 2 of 6 physical-fatigue trials), then concluded: "Research regarding R. rosea efficacy is contradictory… All of the included studies exhibit either a high risk of bias or have reporting flaws that hinder assessment of their true validity."⁸

The three most-cited positive trials — 56 physicians on night duty in 2000, 161 military cadets in 2003, and 60 people with stress-related fatigue in 2009 — all tested the same branded extract, SHR-5.¹¹¹²¹⁰ They also share co-authors: Panossian appears on two and Wikman on two, and their published affiliation is Swedish Herbal Institute Research and Development, the extract's maker.¹³ That doesn't make the results fake. It does mean the positive fatigue literature is not independent — the condition under which a body of evidence tends to look better than it is.

And then there is the trial nobody quotes. In 2014 the University of Alberta group that wrote the systematic review above — the one calling for "a rigorously-designed well reported RCT that minimizes bias"⁸ — went and ran one. Forty-eight nursing students on shift work were randomized to 364 mg of rhodiola or identical placebo daily for 42 days.⁹ On the primary outcome, the RAND-36 Vitality subscale, the day-42 between-group difference was −17.3 (95% CI −30.6 to −3.9, p = 0.011) in favor of placebo; on the cross-validating VAS-Fatigue scale it was 1.9 (95% CI 0.4 to 3.5, p = 0.015), also favoring placebo.⁹ The authors' conclusion: a 42-day course of rhodiola "compared with placebo worsened fatigue," with the caveat that the result "should be interpreted with caution."⁹ One trial settles nothing on its own. But the best-designed independent test of rhodiola for fatigue came out negative — exactly the kind of result that goes missing from a "7 proven benefits" listicle.

Stress symptoms and burnout

CLimited evidence

One genuinely controlled trial exists. Sixty adults meeting Swedish national criteria for fatigue syndrome took 576 mg/day of SHR-5 or placebo for 28 days. Both groups improved on burnout, mental health and depression scores — the placebo effect was large — but the between-group comparison still favored rhodiola on the Pines burnout scale and three attention measures.¹⁰ A real result, with the manufacturer-affiliation caveat above attached.

Almost everything else marketed as burnout evidence is uncontrolled. The 118-patient trial of the WS® 1375 extract was an "exploratory, open-label, multicenter, single-arm trial" with no placebo group, co-authored by an employee of Willmar Schwabe GmbH & Co. KG, which makes that extract.¹⁴ A 100-subject fatigue study of the same extract was likewise "uncontrolled, open-label."¹⁵ Both report improvement showing up inside the first week, and in the 100-subject study week one was the single biggest change.¹⁴¹⁵ In an unblinded fatigue study, "people felt better after a week" is precisely the shape of a placebo response — which is why these two raise a hypothesis rather than settle one, and why this row is a C. Our supplements for stress ranking puts rhodiola next to the alternatives.

Lowering cortisol

DInsufficient evidence

"Rhodiola lowers cortisol" is one of the most repeated sentences in the adaptogen category, and the human evidence is a single secondary outcome in a single small trial. In that 2009 study of 60 people, "pre- versus post-treatment cortisol responses to awakening stress were significantly different in the treatment group compared with the control group."¹⁰ That is a change in the cortisol awakening response in the 30 people who took the extract — not a demonstration that resting or serum cortisol falls. It has never been replicated, and no meta-analysis supports it.

This is the clearest place to compare our two adaptogen hubs, and the gap is not stylistic. Ashwagandha earns a B for cortisol because multiple randomized trials measured serum cortisol against placebo and found it lower. Rhodiola gets a D because one trial measured a different thing once and nobody checked again. Same shelf, same marketing language, two very different piles of evidence — ashwagandha vs rhodiola works through the choice use case by use case.

Anxiety

DInsufficient evidence

There is no placebo-controlled trial of rhodiola for anxiety. The two studies people cite are a 10-person open-label pilot in generalized anxiety disorder, with no control group at all,¹⁶ and an 80-person trial randomized against a no-treatment control — the authors state plainly that "this was a non-placebo controlled trial."¹⁷ Anxiety measures are self-reported and highly placebo-responsive, so unblinded studies are close to uninformative here.

The external check comes from the WFSBP/CANMAT taskforce, 31 academics and clinicians from 15 countries. Ashwagandha, galphimia and lavender were "modestly supported in the treatment of anxiety disorders."¹⁸ Rhodiola is not on that list.¹⁸ Anxiety disorders are common, and they are a clinical question rather than a supplement one — if that's what you're managing, start with a clinician.

Depression and low mood

DInsufficient evidence

The same taskforce is explicit: "rhodiola use was not supported for use in mood disorders."¹⁸ The Merck Manual notes the same conclusion.³ One nuance in rhodiola's favor: that taskforce only assessed Grade A evidence — meta-analyses or two or more randomized trials — and says outright that "an absence of data does not imply lack of efficacy."¹⁸ Rhodiola failed the bar partly because the trials to clear it with don't exist.

The best trial that does exist is a 57-person, 12-week comparison of rhodiola, sertraline and placebo. It found "modest, albeit statistically non-significant, reductions" on all three depression scales, with no significant difference between the groups (p = 0.79, 0.28 and 0.17).¹⁹ Sertraline's decline on the Hamilton scale was larger (−8.2) than rhodiola's (−5.1) or placebo's (−4.6), but the study was a proof-of-concept, underpowered to separate them.¹⁹ What it did find clearly was tolerability: adverse events were reported by 63.2% on sertraline versus 30.0% on rhodiola and 16.7% on placebo.¹⁹ Being gentler than an SSRI is not the same as working like one.

Depression is a diagnosable medical condition. Nothing on this page is a treatment for it, and rhodiola should not replace or be added to prescribed care without your prescriber's sign-off — the safety section explains why that last part is not boilerplate.

Altitude sickness

DInsufficient evidence

The traditional use is genuine — rhodiola is widely used for altitude in the Himalayas and Tibet — and the trial evidence is null. In the only properly designed test, 102 people took 800 mg/day of Rhodiola crenulata extract or placebo for seven days before ascent and two days during, then ascended rapidly from 250 m to 3,421 m, crossing over after a three-month washout.²⁰ Acute mountain sickness incidence was 60.8% in both conditions (adjusted odds ratio 1.02, 95% CI 0.69–1.52), and severe cases ran 35.3% on the extract versus 29.4% on placebo — numerically worse, not statistically significant.²⁰ Two caveats in rhodiola's favor: it tested R. crenulata, not R. rosea, and it is one study. Neither changes the fact that the single best test found nothing.

Weight loss and fat burning

DInsufficient evidence

No human trial has tested rhodiola on its own for weight or body-fat loss. The studies cited in weight-loss marketing are multi-ingredient formulas — where any effect could belong to any component — or rodent models. This row exists because "rhodiola for weight loss" is a real search and every page answering it either dodges or invents. There is nothing here to grade.

"Benefits for men" and "benefits for women": the honest answer

Both phrases are heavily searched and neither has evidence under it. No trial has been designed to test sex-specific effects of rhodiola. The populations were mixed and small — the 2023 sports-performance review covered 263 participants across 13 studies, 198 men and 65 women⁶ — nowhere near enough to detect a sex difference if one existed. Articles promising "7 rhodiola benefits for women" are keyword artifacts: the same thin general evidence, re-titled.

The one place sex genuinely matters is pregnancy and breastfeeding, where there's no safety data at all and the answer is to avoid it. If you came for the male-hormone angle that dominates adaptogen marketing, that question has real data on the other adaptogen — ashwagandha for men grades testosterone and fertility separately, and even there the honest grade is a C.

Rosavins, salidroside, and the product you're actually buying

This is the section nobody writes, and for a real buyer it may be the most useful one on the page.

What the label spec means. An extract standardized to 3% rosavins and 1% salidroside tells you roughly how concentrated the actives are and — because rosavins are the species marker — that the material was checked for being R. rosea at all. Standardization to salidroside alone tells you nothing about species, because salidroside is common across the genus.²² "500 mg of rhodiola root powder," unstandardized, tells you almost nothing at all.

Species substitution is documented. In one analysis of 45 commercial samples from retailers, markets and the internet in China and the UK, 8 of the 11 samples labeled R. rosea (72.7%) contained other Rhodiola species — four of them R. crenulata.²² A UK study of 39 products found about 25% of the unregistered supplements labeled R. rosea were substituted, one adulterated with synthetic 5-HTP.²² The samples are small and the picture isn't uniformly bad — an unpublished 2008 analysis of 20 North American products found rosavins in every one — and the bulletin flags an honest confounder: rosavins can degrade enzymatically if material is handled poorly, so their absence isn't automatically fraud.²²

Label accuracy on the US market. The newest data is a 2026 analysis by University of California, Irvine pharmacy researchers of 10 rhodiola products bought on Amazon — 7 capsules and 3 tinctures.²¹ Measured rosavins ranged from 0.01% to 3.08% and salidroside from 0.07% to 2.91%, "including substantial aberrations from advertised biomarker amounts."²¹ One capsule labeled 3.0% rosavins measured 1.510%; another labeled 1.0% measured 0.191% — about a fifth of its claim.²¹ A third paired low rosavins with a 15-fold higher salidroside concentration, which the authors read as likely undisclosed synthetic salidroside.²¹ All seven capsules carried trace arsenic, cobalt and lead, two at levels flagged for follow-up.²¹ Ten products is a small sample and doesn't mean most rhodiola is fake — it means you can't assume the number on the front of the bottle is in the bottle.

Why this is happening. Since 23 February 2023, all Rhodiola species sit in CITES Appendix II, covering all parts and derivatives except seeds, pollen, and finished products packaged and ready for retail trade.²³ (That last exception is why your capsules come without paperwork — the control is on raw material, not the shelf.) It followed documented wild decline: most rhodiola is still wildcrafted, the plant takes years to regenerate, and "resource depletion and habitat destruction have led to the disappearance of Rhodiola species in many locations."²² The Department of Defense's supplement-safety program gives the mechanism in one line: "a surge in the global demand for Rhodiola rosea has put a strain on the harvesting areas and supply," meaning "such products could be adulterated and potentially unsafe."⁴ Tight supply, rising demand, and species that are practically impossible to tell apart by eye once the root is dug and powdered: the textbook setup for substitution.²²

What to do with that. Buy an extract standardized to rosavins and salidroside; prefer third-party testing and traceable, cultivated sourcing; treat unstandardized root powder as an unknown. It also reframes the anecdotes: if one person's bottle changed their life and another's did nothing, the two bottles may not have held the same plant.

This hub carries no affiliate links and no product picks. That is deliberate — a page arguing that the category has a label-accuracy problem should not also be selling you a bottle. Buying guidance lives in our reviews and comparisons.

How much, and when

The studied doses cluster tightly: 200–600 mg/day of a standardized extract, with 400 mg/day the single most common — it's the dose both open-label WS® 1375 studies used,¹⁴¹⁵ and the amount the second of them names as the recommended daily dosage for the licensed herbal medicine.¹⁵ The placebo-controlled trials sit in that band too: 364 mg/day in the nursing-student trial, with an optional additional capsule taking some participants to 546 mg,⁹ and 576 mg/day in the stress-related fatigue trial.¹⁰ The acute endurance protocol is simpler: a single ~200 mg dose about an hour before exercise.⁷ Higher isn't obviously better — the endurance meta-analysis found greater VO2max gains above 600 mg/day, but that's a subgroup analysis, not a dose-ranging trial.⁵

Timing is a judgment call, not a finding. Rhodiola is activating for some people and insomnia is on NCCIH's side-effect list,¹ so morning or early afternoon is the sensible default. The ubiquitous "empty stomach, 30 minutes before breakfast" rule doesn't come from a trial — the full dosing and timing breakdown, including where that rule came from, is in rhodiola dosage and timing. These are the amounts that were studied, not a prescription.

Safety: better tolerated than ashwagandha, and much less studied

Rhodiola's short-term safety record is genuinely mild. NCCIH lists the reported side effects as "dizziness, headache, insomnia, and either dry mouth or excessive saliva production,"¹ and the Department of Defense's program agrees they "appear to be minimal."⁴ There is no liver-injury signal of the kind our ashwagandha side effects guide works through. But "few reported side effects" partly reflects how little rhodiola has been studied, and three things are worth knowing first.

The interaction almost nobody mentions is CYP2C9. In a randomized crossover study, 13 healthy volunteers took a commercial rhodiola product for 14 days; researchers measured a statistically significant 21% reduction in CYP2C9 activity (p = 0.023) via a losartan probe, with no significant effect on the four other enzymes tested.²⁵ Their conclusion: "although the effect is modest, it might be clinically relevant during treatment with CYP2C9 substrates with a narrow therapeutic index, such as phenytoin and warfarin."²⁵ NCCIH separately notes that "interactions between rhodiola and losartan… have been reported,"¹ and Memorial Sloan Kettering adds CYP3A4 and P-glycoprotein inhibition — both from preclinical work, with clinical relevance it describes as yet to be determined.² If you take a blood thinner, an anti-seizure drug or blood-pressure medication, that's a pharmacist conversation before it's a supplement decision.

Antidepressants and mania — case reports, treated as case reports. Rhodiola shows monoamine oxidase A and B inhibition, and Memorial Sloan Kettering advises caution with prescription antidepressants, citing a 26-year-old woman who reached an emergency department with a fast, irregular heartbeat after three days of rhodiola alongside her antidepressant.² A separate case describes a 68-year-old woman on paroxetine who developed restlessness and trembling after adding rhodiola, read by the authors as a serotonergic syndrome,²⁷ and a 2022 report documents mania associated with rhodiola.²⁶ Three case reports across a widely used supplement is not a rate and shouldn't be read as one — but if you take a serotonergic antidepressant, or have any history of mania, they're a reason to check first rather than experiment.

Pregnancy and breastfeeding: unknown, not proven safe. NCCIH's wording is exactly right: "little is known about whether it's safe to use rhodiola during pregnancy or while breastfeeding."¹ That is a different claim from ashwagandha's, which carries specific reports of abortifacient potential; rhodiola's is a plain absence of data. The practical answer is the same — avoid it — but the reason matters, and we won't borrow a stronger warning than the evidence supports. Full breakdown: rhodiola side effects.

How long should you take it?

NCCIH's ceiling is explicit: rhodiola "is possibly safe for up to 12 weeks."¹ That is the edge of the map — the Department of Defense's program agrees that at 600 mg it appears safe for up to 12 weeks but "the safety of long-term use is unknown."⁴ Unstudied is not the same as unsafe. It is also not the same as safe.

Cycling advice — a few weeks on, a week off — is convention, not evidence: no trial has tested a schedule, and there is no established optimal duration. What the literature does support is treating rhodiola as a time-limited experiment rather than a permanent habit. Run it for the length of an actual trial, then decide whether it did anything.

Who it's for, and who should skip it

A defensible way to use rhodiola: an 8-to-12-week, one-variable trial for stress-linked physical or mental fatigue, at 200–600 mg/day of an extract standardized to rosavins and salidroside, taken in the morning, with a stop rule set in advance. Or, separately, a single ~200 mg dose about an hour before an endurance session — the one context where the timing evidence is specific. Judge it on whether your fatigue actually changed, and remember the best independent fatigue trial came out on placebo's side. A C-grade supplement is worth a fair test, not a standing order.

Skip it if you are pregnant, might become pregnant, or are breastfeeding; if you take warfarin, phenytoin, losartan or other blood-pressure medication without your prescriber's sign-off; if you take a serotonergic antidepressant; or if you have bipolar disorder or any history of mania. And skip it if you're buying for cortisol, anxiety, depression, altitude sickness or weight loss — the five D's on this page, where the honest answer is that it probably won't do that. For stress, ashwagandha has the better evidence; for a pre-workout endurance nudge, rhodiola has the better case.

This page is educational information, not medical advice. Your clinician and pharmacist know your history and your medication list; this page does not.

Frequently asked questions